Merck’s Q1 Earnings Beat Led By Keytruda, And The Momentum Could Continue In The Near Term

By Trefis Team, Contributor Merck (NYSE:MRK) recently reported its Q1 2019 results, which were above our estimates. This note details the company’s Q1 performance, and Trefis’ forecasts for the full year 2019. You can view our interactive dashboard analysis ~ How Did Merck Fare In Q1, And What Can We Expect From Full Year … …read more

Read more here::